Payment overview · 2025
General Payments
$1,982.35
94 reported records · 26 companies
Healthcare provider profile · identity verified
William Chunghun Sim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DOWNEY, CA · NPI 1437256906
Verified facts
What the public records show
CMS Open Payments records show William Chunghun Sim, MD received $1,982.35 in general payments during 2025 across 94 reported records.
ABBVIE INC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Paxlovid, Rexulti, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 768 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 453 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $478.66 | 24.1% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $164.09 | 8.3% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.38 | 8.1% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.32 | 8.0% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $155.80 | 7.9% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $120.01 | 6.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.35 | 4.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $69.36 | 3.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.38 | 3.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.46 | 2.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.84 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.66 | 2.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.66 | 2.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.31 | 2.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.23 | 1.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $37.22 | 1.9% | 2 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $32.10 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.13 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.05 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.35 | 1.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.16 | 1.0% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $18.97 | 1.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.94 | 0.9% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.55 | 0.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.19 | 0.8% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $14.18 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,982.35 | 94 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $265.88 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $153.61 | 6 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $128.90 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $127.26 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $104.74 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.28 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.40 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $79.72 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.08 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $69.36 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $67.10 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.35 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.64 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.39 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.39 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.38 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.17 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.46 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $56.17 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.84 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.66 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $49.40 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $44.15 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.57 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.31 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $32.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 202 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 217 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 768 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 235 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 52 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
202 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
768 | 132 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
35 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
235 | 33 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
453 | 70 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 51 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2063 | 400 |
| Losartan Potassium | Losartan Potassium | 1669 | 319 |
| Amlodipine Besylate | Amlodipine Besylate | 1383 | 265 |
| Metformin Hcl | Metformin Hcl | 1224 | 243 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1215 | 245 |
| Metoprolol Succinate | Metoprolol Succinate | 1005 | 200 |
| Pantoprazole Sodium | Pantoprazole Sodium | 800 | 155 |
| Omeprazole | Omeprazole | 795 | 166 |
| Linzess | Linaclotide | 768 | 132 |
| Donepezil Hcl | Donepezil Hcl | 750 | 96 |
| Gabapentin | Gabapentin | 710 | 112 |
| Tamsulosin Hcl | Tamsulosin Hcl | 683 | 131 |
| Potassium Chloride | Potassium Chloride | 674 | 132 |
| Memantine Hcl | Memantine Hcl | 650 | 92 |
| Montelukast Sodium | Montelukast Sodium | 583 | 108 |
| Doxazosin Mesylate | Doxazosin Mesylate | 562 | 119 |
| Furosemide | Furosemide | 543 | 118 |
| Memantine Hcl Er | Memantine Hcl | 472 | 65 |
| Eliquis | Apixaban | 453 | 70 |
| Famotidine | Famotidine | 444 | 77 |
| Meloxicam | Meloxicam | 428 | 93 |
| Glipizide Er | Glipizide | 416 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 391 | 77 |
| Prednisone | Prednisone | 385 | 186 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 377 | 152 |
| Mirtazapine | Mirtazapine | 368 | 68 |
| Finasteride | Finasteride | 338 | 56 |
| Simvastatin | Simvastatin | 329 | 72 |
| Risperidone | Risperidone | 325 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 305 | 50 |
| Januvia | Sitagliptin Phosphate | 304 | 45 |
| Lisinopril | Lisinopril | 300 | 78 |
| Sertraline Hcl | Sertraline Hcl | 297 | 56 |
| Loperamide | Loperamide Hcl | 291 | 163 |
| Quetiapine Fumarate | Quetiapine Fumarate | 288 | 37 |
| Trazodone Hcl | Trazodone Hcl | 281 | 58 |
| Lorazepam | Lorazepam | 269 | 58 |
| Azithromycin | Azithromycin | 267 | 208 |
| Hydralazine Hcl | Hydralazine Hcl | 258 | 52 |
| Alprazolam | Alprazolam | 240 | 48 |
| Lidocaine | Lidocaine | 236 | 42 |
| Ozempic | Semaglutide | 235 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 235 | 108 |
| Restasis | Cyclosporine | 233 | 39 |
| Vascepa | Icosapent Ethyl | 231 | 35 |
| Tramadol Hcl | Tramadol Hcl | 230 | 69 |
| Ezetimibe | Ezetimibe | 228 | 67 |
| Jardiance | Empagliflozin | 217 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 44 |
| Alendronate Sodium | Alendronate Sodium | 212 | 43 |
| Carvedilol | Carvedilol | 207 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 205 | 50 |
| Levofloxacin | Levofloxacin | 203 | 145 |
| Creon | Lipase/Protease/Amylase | 202 | 38 |
| Glipizide | Glipizide | 183 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 182 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 43 |
| Atenolol | Atenolol | 178 | 38 |
| Tradjenta | Linagliptin | 171 | 17 |
| Celecoxib | Celecoxib | 170 | 24 |
| Allopurinol | Allopurinol | 159 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 25 |
| Clonidine Hcl | Clonidine Hcl | 156 | 44 |
| Raloxifene Hcl | Raloxifene Hcl | 154 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 147 | 23 |
| Megestrol Acetate | Megestrol Acetate | 145 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 144 | 25 |
| Pregabalin | Pregabalin | 141 | 21 |
| Metolazone | Metolazone | 140 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 30 |
| Latanoprost | Latanoprost | 136 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 51 |
| Ibuprofen | Ibuprofen | 131 | 53 |
| Sucralfate | Sucralfate | 120 | 20 |
| Methimazole | Methimazole | 119 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 32 |
| Naproxen | Naproxen | 115 | 32 |
| Valsartan | Valsartan | 109 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 21 |
| Myrbetriq | Mirabegron | 101 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 30 |
| Cyclosporine | Cyclosporine | 99 | 30 |
| Benazepril Hcl | Benazepril Hcl | 97 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 26 |
| Farxiga | Dapagliflozin Propanediol | 80 | 17 |
| Meclizine Hcl | Meclizine Hcl | 80 | 35 |
| Repaglinide | Repaglinide | 80 | 18 |
| Glimepiride | Glimepiride | 77 | 13 |
| Levetiracetam | Levetiracetam | 77 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 72 | 27 |
| Icosapent Ethyl | Icosapent Ethyl | 72 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 26 |
| Entresto | Sacubitril/Valsartan | 71 | suppressed |
| Primidone | Primidone | 70 | 12 |
| Spironolactone | Spironolactone | 70 | 19 |
| Divalproex Sodium | Divalproex Sodium | 69 | 15 |
| Nifedipine Er | Nifedipine | 69 | 16 |
| Olanzapine | Olanzapine | 69 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 20 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 68 | suppressed |
| Temazepam | Temazepam | 68 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 54 |
| Flecainide Acetate | Flecainide Acetate | 65 | suppressed |
| Risperidone Odt | Risperidone | 65 | 12 |
| Aripiprazole | Aripiprazole | 64 | 12 |
| Irbesartan | Irbesartan | 61 | 12 |
| Midodrine Hcl | Midodrine Hcl | 60 | 15 |
| Dutasteride | Dutasteride | 59 | suppressed |
| Ofloxacin | Ofloxacin | 59 | 50 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 11 |
| Bethanechol Chloride | Bethanechol Chloride | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 15 |
| Topiramate | Topiramate | 53 | suppressed |
| Digoxin | Digoxin | 52 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 51 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 49 | 11 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 35 |
| Brimonidine Tartrate | Brimonidine Tartrate | 47 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 47 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 45 | suppressed |
| Folic Acid | Folic Acid | 45 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 30 |
| Klor-Con 10 | Potassium Chloride | 40 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 22 |
| Fluconazole | Fluconazole | 39 | 29 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 25 |
| Estradiol | Estradiol | 36 | suppressed |
| Permethrin | Permethrin | 36 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 24 |
| Prolia | Denosumab | 35 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 15 |
| Enulose | Lactulose | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 17 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Lactulose | Lactulose | 29 | 12 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clotrimazole | Clotrimazole | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Tolvaptan | Tolvaptan | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Alphagan P | Brimonidine Tartrate | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 19 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Ursodiol | Ursodiol | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Minoxidil | Minoxidil | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 13 |
| Fluocinonide | Fluocinonide | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 18 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 11 |
| Nystop | Nystatin | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Brinzolamide | Brinzolamide | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Entacapone | Entacapone | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 12 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Prolensa | Bromfenac Sodium | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Exelon | Rivastigmine | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,982.35 · 94 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, CONTRAVE, CREON, Dexcom G6 Transmitter, FARXIGA, Fibroscan, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OFEV, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, Xhance, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error